LifeMine Therapeutics, a biopharmaceutical company reinventing drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, has completed a USD175 million Series C financing.

The financing was led by new investor Fidelity Management & Research Company, with participation by additional new investors Invus and 3W Partners Capital; GlaxoSmithKline (GSK) also joined the round as a strategic partner. 

Existing investors, including GV, Arch Venture Partners, Blue Pool Capital and MRL Ventures Fund, also participated.

Proceeds from the financing will be used to advance LifeMine’s proprietary, evolutionarily-derived genomic drug discovery platform, Avatar-Rx.